



The Global Leader in Gamma-Delta T-Cell Therapy

Investor Presentation

Q1 2025

Forward Looking Statements

This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act, as amended, regarding future events and the future results of the TC BioPharm (Holdings) plc and its subsidiaries (the together, the “Company”). These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions of the management of the Company which the management deems reasonable. Any discussion of performance, historical or otherwise, reflects the performance of such assets prior to the formation of the TC BioPharm (Holdings) plc, the issuer. Words such as “address,” “anticipate,” “believe,” “consider,” “continue,” “develop,” “estimate,” “expect,” “further,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “target,” “will,” variations of such words, and similar expressions are intended to identify such forward-looking statements. Such statements reflect the current views of the Company and its management with respect to future events and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. This presentation has been prepared by the Company based on information it has obtained from sources it believes and has reason to believe to be reliable. Summaries of documents contained in this presentation may not be complete. The Company does not represent that the information herein is complete. The information in this presentation is current only as of January 2024, and the Company’s business or financial condition and other information in this presentation may change after that date. The Company undertakes no obligation to update any forward-looking statements in order to reflect any event or circumstance occurring after the date of this presentation or currently unknown facts or conditions.

In particular, this presentation contains projected financial information with respect to the Company. Such projected financial information constitutes forward-looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Actual results may differ materially from the results contemplated by the projected financial information contained in this presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such projections will be achieved.


This presentation may not be copied or reproduced in whole or in part. By accepting delivery of this presentation, you agree to these restrictions.

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of **gamma-delta T-cell therapies** for the treatment of cancer with human efficacy data in acute myeloid leukemia.

Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.


As a leader in the space, we are the **first company to conduct phase II/pivotal clinical studies in oncology.**

TCBP Investment Highlights



Combined Clinical Development Pipeline


Next generation GDT cell therapies for both solid tumors and blood cancers

Program	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Status / Upcoming Milestone
TCB008 (Vδ2 subtype) Allogeneic (Unmodified)	AML					Phase 1b/2a complete H1 2020 – PR & CR achieved Phase 2b launched, 6 patients dosed (High Dose)
TCB008 (Vδ2 subtype) Allogeneic (Unmodified)	AML					Received FDA clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML)
CAR-T Acquisition Assets	Solid Tumors					Granted MHRA Clinical Trial Authorization for Lateral NKG2D CAR-T Cell Therapy
Anti-Fungal	Aspergillus / Candida					Proof of Concept & Pre-clinical Work
Anti-Viral	MPOX					Proof of Concept & Pre-clinical Work
CAR-NK Acquisition Assets	Renal Carcinoma / NSCLC					Demonstrated tumor regression and functional persistence in multiple CD70 expressing tumor models Efficacy established in multiple xenograft models



TCB008 Lead Program





ACHIEVE (UK) Phase 2b Data

Opened a **new clinical site**, Guys and St. Thomas Hospital in the ACHIEVE UK Trial

Opening new UK-based sites, specializing in **hematology**, in H1 2025

End of Stage One Interim Analysis May – Aug 2025

End of Study Analysis Dec 2025 – Feb 2026

ACHIEVE2 (US)

Amendment to Progress US Study using ACHIEVE (UK) Study Data in H2 2025;


- Patient Treatment in 2026

TCB008 Pre-Clinical Studies: Cytotoxicity against AML Cell Lines

- Three lots of TCB008 were tested against a panel of AML cell lines for their ability to specifically eradicate/kill the cancer cells.
- Within 24 hours of exposing AML cell lines to TCB008 drug product, TCB008 exhibited substantial cytotoxic effects against all 3 AML cell lines.
- TCB008 lots were manufactured from starting material obtained from 3 different donors who met TCBP's criteria for donor selection.


E = Effectors

T = Targets



TCB008 Pre-Clinical Studies: *In Vitro* Safety Testing

- TCB008 safety was confirmed in an off-target cytotoxicity assay against primary human monocyte-derived macrophages, a healthy counterpart for AML.
- TCB008 at doses of Effector : Target ratios that exhibited potent cytotoxicity against 2 cancer cell lines did not exhibit off-target cytotoxicity against healthy control cells.




THP-1 – AML Cell Line

T98G – Glioblastoma Cell Line

TCB008 Pre-Clinical Studies: *In Vitro* Safety Testing Cont.

- As TCB008 is a systemic infusion, safety was confirmed against representative healthy tissues from human skin, kidneys, and lung.
- TCB008 was not cytotoxic against healthy human tissues at the effector : target doses that exhibited potent cytotoxicity against cancer cells.
- In vitro data indicate that TCB008 is effective against AML cells whilst maintaining a suitable safety profile.



THP-1 – AML Cell Line

T98G – Glioblastoma Cell Line

NHDF – Primary Normal Human Dermal Fibroblasts

HREC – Primary Human Renal Epithelial Cells

HUVEC – Human Umbilical Vein Endothelial Cells (Cell Line)

HPMEC – Primary Human Pulmonary Microvascular Endothelial Cells

ACHIEVE Phase 2b Trial Overview

An adaptive trial of the efficacy and effectiveness of adoptive cellular therapy with ex vivo expanded allogeneic $\gamma\delta$ T-lymphocytes (TCB008) for patients with refractory or relapsed acute myeloid leukemia (AML)

Study Objectives:

- Primary Objective: Evaluate the efficacy and effectiveness of TCB008 in treating refractory or relapsed AML or MDS/AML
- Secondary Objective: Assess the safety of TCB008 in the patient population.
- Exploratory Objectives: To evaluate the persistence and proliferation of TCB008 in vivo

Number of Patients:

- Cohort A will recruit 24 patients with primary refractory AML, or MDS/AML who have
 - Not achieved a complete response after two cycles of induction chemotherapy; or,
 - Relapsed after initially achieving a complete response to previous chemotherapy
- Cohort B: will recruit 24 patients with AML or MDS/AML who have achieved a complete response but have a detectable residual disease

Dosing Regime:


- Flat dose containing 5 mL TCB008 (12.0×10^7 to 23.0×10^7 cells)
- Four doses in total, one dose every two weeks

Data Analysis:

- Interim analysis of each cohort independently after 14 patients

Participating Study Sites:

- King's College Hospital, London
- Guy's and St. Thomas Hospital, London
- Royal Marsden Hospital, London
- Queen Elizabeth University Hospital, Glasgow



Safety Cohort:

- Five patients were recruited for a single 1.8 mL dose of TCB008 (3.2×10^7 to 9.5×10^7 cells)
- No TCB008 drug-related adverse events
- Preliminary data showed stable disease in two patients (40%)
- Data Safety Monitoring Board advised dose escalation from 1.8 to 5 mL based on preliminary safety and efficacy results

New 4 x 5mL Dosing Regime:

- 16 Patients screened
- 11 Patients enrolled
- 8 patients dosed with 5mL TCB008;
 - 6 patients have received their first and second dose
 - 4 patients have received their third dose
 - 3 patient has received their fourth and final dose
- Projected recruitment of a further 3 patients per month

Preliminary safety data:

- 5 mL dose is well-tolerated.
- No adverse events related to TCB008 in the first six patients treated with 5 mL TCB008
 - Adverse events are related to chemotherapy
 - 1 Patient with TP53 mutation withdrew due to disease progression, unrelated to TCB008



Competitive Landscape



Cell-based Immunotherapy Landscape

Company	Lead Indication	Pre-Clinical	Phase 1 / 2	Phase 2 / 3
	AML			
	NHL			
	HAEM & CNS			
	Lung Cancer			
	Solid Tumors			
	Solid Tumors			




2025 Strategic Initiatives



TC BioPharm's GDT, NK Cell and CAR-T assets provide a unique product development platform targeting blood cancer and solid tumors

- TCB has established history of advancing cell therapies from autologous to allogeneic rapidly due to R&D expertise.
- Translational expertise across cell types and new CAR technologies.

- Vertically integrated approach, from R&D to product manufacturing, allows for efficient and rapid technology advancement.



- TCBP seeks to opportunistically pursue complimentary cell therapy companies
 - Market conditions provide attractive valuations for desirable assets.
 - Currently negotiating with specific acquisition targets
 - Candidates would provide both stand alone treatments and complimentary therapeutics
- Capable of developing proprietary $\gamma\delta$ T cell therapy platforms, which can support a pipeline of innovative cell therapies
- TCB008 has an ideal profile for combination therapies
 - No drug related toxicity
 - Allogeneic, and no expected drug on drug interaction
- Company focus for TCB008 will be on multiple exclusive partnerships/agreements for TCB008 in Combination trials
 - Upfront payments, non-dilutive with royalty agreements



- TCBP entered into a collaboration agreement with **Queen Mary University of London** (QMUL) to research the therapeutic potential of **gamma-delta T cells** for treating **mucosal infections**
 - The collaboration recently received grant funding from The Impact Fund arm of QMUL
- Formed research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for **Monkeypox**
 - Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the **University of Surrey, United Kingdom** and works closely with **The Pirbright Institute**, a leading center of excellence in research of viral diseases that spread from animals to humans
- The Company entered into a sponsored research agreement with **Carnegie Mellon University** to explore the potential use of **artificial intelligence** to optimize the patient screening process.
 - TCBP will partner with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the School of Computer Science at the renowned university, and her lab to leverage **AI** to build a solution that enhances the donor selection process and matching process



Milestones

Antifungal Proof of Concept by EOY 2024

Mpox Proof of Concept in 2025

Formed **Artificial Intelligence** Initiative with Partner **Carnegie Mellon** University for Donor Screening;

- Use of **AI** to Identify Donors in 2025

Manufacturing at Increased Scale by Oct 2025

Completed **\$6.0 Million Public Offering**

Streamlined the organization to drive process-related efficiencies and reduced headcount by approximately 50%



ACHIEVE (UK) Phase 2b Data

Opened a **new clinical site**, Guys and St. Thomas Hospital in the ACHIEVE UK Trial

Opening new UK-based sites, specializing in **hematology**, in H1 2025

End of Stage One Interim Analysis May – Aug 2025

End of Study Analysis Dec 2025 – Feb 2026

ACHIEVE2 (US)

Amendment to Progress US Study using ACHIEVE (UK) Study Data in H2 2025;

- Patient Treatment in 2026

MASON assets and **LION** by Q2 2025

Two further acquisitions in H2 2025



Thank you

Chris Camarra
EVP, Communications
TC Biopharm
c.camarra@tcbiopharm.com